Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bjorl.2020.12.002 http://scihub22266oqcxt.onion/10.1016/j.bjorl.2020.12.002 33441276!7831803!33441276     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Braz+J+Otorhinolaryngol 2022 ; 88 (3): 439-444 Nephropedia Template TP {{tp|p=33441276|t=2022. Olfactory dysfunction in COVID-19: a marker of good prognosis?|pdf=|usr=}}{{33441276}} gab.com Text Olfactory dysfunction in COVID-19: a marker of good prognosis JO: Braz J Otorhinolaryngol http://www.kidney.de/pget.php?&tw=1&pmid=33441276 #FOAvip INTRODUCTION: In May 2020, the World Health Organization recognized olfactory dysfunction as a COVID-19 symptom. The presence of hyposmia/anosmia may be a marker of good prognosis in COVID-19. OBJECTIVE: To associate the presence of olfaction disorder to the clinical condition severity in patients with COVID-19. METHODS: Individuals with the flu syndrome caused by SARS-CoV-2, diagnosed from March to June 2020, were recruited. They were divided into three groups: mild flu syndrome, severe flu syndrome (admitted to hospital wards) and critical illness (admitted to the ICU). Inpatients were interviewed by telephone contact after hospital discharge and their medical records were also evaluated regarding complementary test results. Outpatients answered an electronic questionnaire containing only clinical information. RESULTS: A total of 261 patients participated in the study: 23.75% with mild flu syndrome, 57.85% with severe flu syndrome and 18.40% with critical illness. A total of 66.28% patients with COVID-19 had olfaction disorders. In approximately 56.58% of the individuals the smell alterations lasted between 9 days and 2 months. There was a significantly higher proportion of individuals with olfactory dysfunction in the group with mild flu syndrome than in the severe flu syndrome group (mild?x?severe - p?<?0.001; Odds Ratio?=?4.63; 95% CI [1.87-10.86]). This relationship was also maintained between patients with mild flu syndrome and critically-ill patients (mild?x?critical - p?<? 0.001; Odds Ratio = 9.28; 95% CI [3.52-25.53]). CONCLUSION: Olfaction dysfunction was significantly more prevalent in patients with mild flu syndrome in COVID-19. It may be a predictor of a good prognosis for this infection. New population-based studies must be carried out to corroborate these findings. Twit Text FOAVip Olfactory dysfunction in COVID-19: a marker of good prognosis ????Braz J Otorhinolaryngol http://www.kidney.de/pget.php?&tw=1&pmid=33441276 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33441276 #FOAvip English Wikipedia <ref>{{Cite pmid|33441276}}</ref> Olfactory dysfunction in COVID-19: a marker of good prognosis? #MMPMID33441276 Mendonca CV; Mendes Neto JA; Suzuki FA; Orth MS; Machado Neto H; Nacif SR Braz J Otorhinolaryngol 2022[May]; 88 (3): 439-444 PMID33441276show ga INTRODUCTION: In May 2020, the World Health Organization recognized olfactory dysfunction as a COVID-19 symptom. The presence of hyposmia/anosmia may be a marker of good prognosis in COVID-19. OBJECTIVE: To associate the presence of olfaction disorder to the clinical condition severity in patients with COVID-19. METHODS: Individuals with the flu syndrome caused by SARS-CoV-2, diagnosed from March to June 2020, were recruited. They were divided into three groups: mild flu syndrome, severe flu syndrome (admitted to hospital wards) and critical illness (admitted to the ICU). Inpatients were interviewed by telephone contact after hospital discharge and their medical records were also evaluated regarding complementary test results. Outpatients answered an electronic questionnaire containing only clinical information. RESULTS: A total of 261 patients participated in the study: 23.75% with mild flu syndrome, 57.85% with severe flu syndrome and 18.40% with critical illness. A total of 66.28% patients with COVID-19 had olfaction disorders. In approximately 56.58% of the individuals the smell alterations lasted between 9 days and 2 months. There was a significantly higher proportion of individuals with olfactory dysfunction in the group with mild flu syndrome than in the severe flu syndrome group (mild?x?severe - p? |*COVID-19/complications[MESH] |*Olfaction Disorders/diagnosis/etiology[MESH] |Critical Illness[MESH] |Humans[MESH] |Prognosis[MESH] |SARS-CoV-2[MESH]Olfactory dysfunction in COVID-19: a marker of good prognosis?(epmc).pdf DeepDyve Pubget Overpricing